Qualified Person Education Course

Understand the Implications of Working as a QP

25/26 March 2020, Berlin, Germany

With an optional pre-course Session:
“Investigational Medicinal Products (IMP) QP Education Course” on 24 March 2020

Speakers:

Susanne Ding
Boehringer Ingelheim, Germany

Dr Ulrich Kissel
European QP Association

Savvas Koulouridas
Fagron BV, The Netherlands

Aidan Madden
FivePharma, Ireland

Sue Mann
Sue Mann Consultancy, U.K.

Rico Schulze
State Ministry of Social Affairs and Consumer Protection, Saxony, Germany

Lance Smallshaw
UCB, Belgium

Brenda Van Assche
Janssen, Belgium

Participants’ comments on the last QP Education Courses

“I learnt many things in the case study” - Naaz Dubash, ProPharma Group B.V., The Netherlands

“More than satisfied with the course!” - Dr. Pavla Holubova, TPI Norway

“Thanks for great opportunity for improving my knowledge and change experience! Excellent Organization!” - Iryna Martynchyk, JSC Pharmaceuticals, Ukraine

“Very enjoyable and engaging.” - Jason Fagg, Leyden Delta B.V., The Netherlands

“Being a senior professional, it has been very helpful for getting overview and confirming confidence in my professional judgment.”
Marc Stegeman, ProPharma Group, The Netherlands
Dear Colleagues,

The European Qualified Person Association (EQPA) has developed this Education Course for new and future Qualified Persons to address general compulsory and regulatory issues. It has been compiled by the EQPA Board of Directors to provide a general idea of the special tasks and responsibilities of a QP, but also to discuss and convey possible solutions to problems addressed in case studies and workshops. Further impacts of the latest developments, specific tasks and further discussions will be part of the annual QP Forum of the European Qualified Person Association.

Best regards,

Ulrich Kissel
Chairman of the European Qualified Person Association

Objectives

Broaden and intensify your knowledge of the Qualified Person’s duties and responsibilities. Experts from the EQPA Board of Directors, pharmaceutical industry and regulatory authority will share their experience on important issues of the QP’s daily business and will give first-hand information on current and future expectations.

Background

Over the last years the role and responsibilities of the Qualified Persons have been increasing considerably. As a key person in the company, the QP has to consider many issues and has to take up the challenges within its areas of responsibilities. Additionally, as laid out in Article 49 of the European Directive 2001/83/EC, the QP needs to be highly qualified and experienced. This education course is one important part to help the QP be on top of current developments in GMP and regulatory requirements.

Target Audience

New and future Qualified Persons, QPs who are looking for ongoing training and personnel who want to get a detailed overview of the role and responsibilities of a QP.

Programme QP Education Course

25/26 March 2020

The Legal and Professional Duties of the Qualified Person
- The Qualified Person within the EU legislation and regulation framework
- Professional tasks, duties and responsibilities
- Expectations of an EU GMP Inspector

Update on European Requirements
- EU GMP Guide Chapters
- EU GMP Guide Annexes
- Other important News
- What the QP needs to be aware of

Delegation of Duties and Responsibilities
- Possible scenarios according to Annex 16
- Mutual Recognition Agreements (MRA)
- Documentation review issues
- The QP in the quality system

Workshop on Case studies:
Certification by a QP and Batch Release - to certify or not, that’s the Question
- Batch release: degrees of freedom and limits
- The QP’s discretion as defined in Annex 16
- Case Studies

What the QP needs to know about Pharmacopoeias
- The world of different Pharmacopoeias
- Pharmacopoeias are more than just Monographs
- How to deal with different methods

Workshop:
Deviations during the Manufacture of an API – What Actions should you take as the responsible QP?

What the QP needs to know regarding the Supply Chain (from Supplier Qualification to GDP)
- The QP: ultimate responsibility for the supply-chain of a drug product?
- What is the expected scope of supply chain oversight
- Supply chain integrity
- Active Pharmaceutical Ingredient, Excipients, Bulk and Finished Product
- Shipping under quarantine, ship to label claim, importation testing
- The role of the QP in supplier qualification and auditing
- Written confirmation and QP Declaration
- GMP meets GDP: where does the responsibility end?
- The QP’s involvement in the recall process
How the QP fits into the Quality Systems

- How much involvement is needed in systems like:
  - Product Quality Review
  - Inspection Management
  - Batch Record Review
  - CAPA
  - Change Control
  - Validation
  - Complaints and recalls
  - Batch certification and release
  - Laboratory investigations

Liability and indemnification

- Liability and indemnification of QPs
- Role and responsibility of head of production and head of quality control (when things go wrong)
- Role and responsibility of upper management (when things go wrong)
- Delimitation of responsibilities with QPs in the same company
- Delimitation of responsibilities with QPs at a contractor

Workshop:
What the QP needs to know about OOS/OOT

- Involvement of the QP
- Role and responsibility of the Head of Quality Control
- Responsibility of the QP

Social Event

On 25 March 2020, you are invited to take part in an evening program in Berlin (tour and Dinner). This is an excellent opportunity to share your experiences with the speakers and colleagues from other companies in a relaxed atmosphere.

Speakers QP Education Course

Dr Ulrich Kissel
European QP Association

Ulrich Kissel is Qualified Person and Chairman of the Board of Directors of the European Qualified Person Association (EQPA). He works as a GMP consultant and contract QP to the Pharmaceutical Industry. Previous to his current role he held leadership positions in Quality and Supply Chain and served for many years as QP for Roche.

Savvas Koulouridas
Fagron BV, The Netherlands

Savvas Koulouridas is Global Innovations Director. He is a lawyer in profession and has also worked as a consultant on pharmaceutical law (GMP regulations and Pharmaceutical Contracts).

Aidan Madden
FivePharma, Ireland

Aidan Madden is CEO of FivePharma, a Quality Services Company founded in 2003. Aidan held senior quality positions in Wyeth Pharmaceuticals, Baxter Healthcare and Fort Dodge Laboratories.

Sue Mann
Sue Mann Consultancy, U.K.

Sue Mann is a Qualified Person and a QP Assessor in the U.K. working on behalf of the MHRA, representing the Royal Pharmaceutical Society. She was Vice President of International Quality Assurance at Shire Pharmaceuticals.

Rico Schulze
State Ministry of Social Affairs and Consumer Protection, Saxony, Germany

Rico Schulze is a Pharmacist and holds a degree in Economics. Before working for the State Ministry, he was GMP and GDP Inspector at the Local Inspectorate in Dresden and performed inspections worldwide.

Lance Smallshaw
UCB, Belgium

Lance Smallshaw is Global Analytical Expert (Global Pharmacopoeias Leader) within the Regulatory Intelligence Network (RIN) in the UCB Site Quality Operations Team. He is also Co-Chair of the Executive Board of ECA and Associate Director and European CMC Strategy Committee member for CaSSS Biopharm.
Pre-course Session: “Investigational Medicinal Products (IMP) QP Education Course” on 24 March 2020

Objectives
This pre-course session provides a detailed overview of the specific characteristics in IMP manufacturing a QP must know to certify IMP batches for the release for clinical trials.

Background
The manufacture of investigational medicinal products (IMPs), including labelling, packaging, testing and certification, is carried out in accordance with the applicable GMP regulations. However, this is not a routine process, since, among other things, manufacturing and packaging procedures might be different for each and every clinical trial. The Qualified Person (QP) must therefore take into account these particularities and the GMP/GCP interface.

Target Audience
New colleagues becoming IMP QPs, QPs looking for continuous training and personnel of CROs and “non-commercial” IMP organisations.

Moderator
Dr Susanne Ding

Programme

General introduction
- Different clinical phases I to IV, focus on patient safety
- Undefined processes (manufacture, fit for purpose control strategy, etc.)
- Why use risk assessments & how to apply – vital core of a IMP quality system
- Diversity: IMP manufacturers, start-ups, academia...

Specific legal requirements for IMPS
- Clinical Trial Regulation EU No. 536/2014 and the “old” Annex 13 and Directives 2001/20/EC and 2003/94/C
- The “new” ATMP regulation

GMP meets clinical trials – Differences between IMPS and commercial Products
- Packaging & labeling
- Randomization
- Blinding / placebos
- Comparators
- NIMPS / AMPs
- Where to apply validation activities
- The Product Specification File (PSF)
- 3rd country manufacture of IMPs: import and the QP Declaration

Registration
- IMPD, CTA, IND etc.
- Regulatory compliance and the two step release procedure

GMP/ GDP/ GCP Interface
- Interaction with clinical sites
- Distribution
- IRT

Speakers IMP QP Education Course

Dr Susanne Ding
Boehringer Ingelheim, Germany
Susanne Ding is Qualified Person for IMPS at Boehringer Ingelheim, Member of the Board of Directors of the European Qualified Person Association (EQPA) and Chair of the IMP Working Group within the EQPA.

Sue Mann
Sue Mann Consultancy, U.K.
Sue Mann is a Qualified Person and a QP Assessor in the U.K. working on behalf of the MHRA, representing the Royal Pharmaceutical Society. She was Vice President of International Quality Assurance at Shire Pharmaceuticals.

Brenda Van Assche
Janssen, Belgium
Brenda Van Assche is Director QA Clinical Supply Chain and Qualified Person for IMPS at Janssen. She is also a member of the IMP Working Group within the EQPA.
About the European QP Association

The European Qualified Person (QP) Association was founded in July 2006 by the European Compliance Academy’s (ECA) Advisory Board Members. With this unique association the ECA wants to provide QPs in Europe with a platform allowing them to exchange their experience, discuss the latest regulatory requirements, to identify and address difficulties and challenges and to support a harmonised European approach.

Who can become member of the QP Association?

Only registered Qualified Persons in Europe can become regular members of the QP Association. Details about the registration of the QP will be required in the application form. Interested persons who want to become a Qualified Person can apply for an associate membership.

How to become member of the QP Association?

To become member please fill in the membership application form available at www.qp-association.eu. Membership is free.

What are the benefits of the membership?

As a member of the European Qualified Person Association you can exchange your experience with other colleagues (e.g. by using the exclusive QP discussion forum), send comments on new Guidances and Directives to EU Authorities through the Association and join the annual QP Forum with a discount of 10%.
Dates
Pre-course Session: IMP QP Education Course
Tuesday, 24 March 2020, 9.00 – 17.30 h
(Registration and coffee 8.30 – 9.00 h)

QP Education Course
Wednesday, 25 March 2020, 9.00 – 18.00 h
(Registration and coffee 8.30 – 9.00 h)
Thursday, 26 March 2020, 8.30 – 15.30 h

Venue for both events
Steigenberger Hotel Berlin
Los-Angeles-Platz 1
10789 Berlin, Germany
Phone +49 (0) 30 21 27 0
Email berlin@steigenberger.d

Fees (per delegate plus VAT)
Pre-course Session: IMP QP Education Course
QP Association Members € 890
ECA Members € 890
Non-ECA/Non-QP Association Members € 990
EU GMP Inspectorates € 795

QP Education Course
QP Association Members € 1,490
ECA Members € 1,490
Non-ECA/Non-QP Association Members € 1,690
EU GMP Inspectorates € 845

Save money when booking both events
If you book the QP Education Course
TOGETHER WITH the Pre-course IMP QP Education Course, the fee will be as follows:
QP Association Members € 1,990
ECA Members € 1,990
Non-ECA/Non-QP Association Members € 2,290
EU GMP Inspectorates € 1,145

Conference language
The official conference language will be English.

Accommodation
CONCEPT has reserved a limited number of rooms in the conference hotel. You will receive a room reservation form/POG when you have registered for the course. Reservation should be made directly with the hotel. Early reservation is recommended.

Reservation Form (Please complete in full)

☒ Qualified Person Education Course – Understand the Implications of Working as a QP
25/26 March 2020, Berlin, Germany

☒ Pre-course Session: IMP QP Education Course
24 March 2020, Berlin, Germany

☐ Mr ☐ Ms

Title, first name, surname

Company

Department

Important: Please indicate your company’s VAT ID Number and your PO Number

Street / PO Box

City Zip Code Country

Phone/Fax

Email (Please fill in)

General terms and conditions
If you cannot attend the conference you have two options:
1. We are happy to welcome a substitute colleague at any time.
2. If you have to cancel entirely we must charge the following processing fees: Cancellation two options:
   - until 10 days after receipt of invoice (as of January 2012).

In case you do not appear at the event without having informed us, you will have to pay the full registration fee, even if you have not made the payment yet. Only after we have received your payment, you are entitled to participate in the conference! (As of January 2012).

German law shall apply. Court of jurisdiction is Heidelberg.

Organisation / Contact
CONCEPT HEIDELBERG
P. O. Box 10 17 64
D-69007 Heidelberg, Germany
Phone +49 (0) 62 21/84 44-0
Fax +49 (0) 62 21/84 44 34
info@concept-heidelberg.de,
www.concept-heidelberg.de

For questions regarding content
please contact:
Mr Wolfgang Schmitt (Operations Director)
at +49 (0) 62 21 / 84 44 39, or per e-mail at w.schmitt@concept-heidelberg.de.

For questions regarding reservation,
hotel, organisation, etc please contact:
Ms Marion Grimm (Organisation Manager)
at +49 (0) 62 21 / 84 44 18, or per e-mail at grimm@concept-heidelberg.de.

Privacy Policy: By registering for this event, I accept the processing of my Personal Data. Concept Heidelberg will use my data for the processing of this order, for which I hereby declare to agree that my personal data is stored and processed. Concept Heidelberg will only send me information in relation with this order or similar ones. My personal data will not be disclosed to third parties (see also the privacy policy at http://www.qp-association.eu). I note that I can ask for the modification, correction or deletion of my data at any time via the contact form on this website.